VIP (6-28) is a truncated form of vasoactive intestinal peptide (VIP), a neuropeptide involved in various physiological functions, such as neurotransmission, smooth muscle relaxation, and hormone regulation.
Gastrointestinal Issues: Common side effects include nausea, vomiting, diarrhea, and abdominal discomfort. These symptoms usually improve over time as the body adjusts to the medication.
Hypoglycemia: As tirzepatide lowers blood sugar levels, it can sometimes lead to hypoglycemia (low blood sugar). The risk of hypoglycemia is generally lower compared to some other diabetes medications, especially when used alone.
Injection Site Reactions: Some individuals may experience mild reactions at the injection site, such as redness, itching, or swelling.
Potential Pancreatitis: Like other GLP-1 receptor agonists, there have been rare reports of pancreatitis associated with tirzepatide. Patients should be monitored for signs and symptoms of pancreatitis, such as severe abdominal pain that may radiate to the back.
Other Side Effects: Other less common side effects might include headache, dizziness, fatigue, and allergic reactions.
Targeted Imaging: PSMA-11 is designed to bind specifically to PSMA, a protein that is often overexpressed in prostate cancer cells. By attaching to PSMA, this radiotracer helps in locating and visualizing prostate cancer cells.
PET Imaging: When labeled with a radioactive tracer (often Gallium-68 or Fluorine-18), PSMA-11 is administered to patients intravenously before PET scans. The radioactive emissions produced by the tracer are detected by the PET scanner, enabling the creation of detailed images of the affected areas in the body.
High Sensitivity and Specificity: PSMA-11 PET imaging is known for its high sensitivity and specificity in detecting small lesions and metastases related to prostate cancer, potentially providing more accurate staging and treatment planning.
Clinical Applications: PSMA-11 PET scans are used for various clinical purposes, including initial staging, localization of recurrence, assessment of treatment response, and monitoring disease progression in patients with prostate cancer.
Research and Development: PSMA-11 is part of ongoing research and development efforts in nuclear medicine and oncology. Researchers continue to explore its potential applications, optimize imaging protocols, and develop newer PSMA-targeted tracers for improved detection and characterization of prostate cancer.
Wuhan Comings Biotechnology Co., Ltd.is a company specializing in the production of Prostamax peptide raw materials. We have our own laboratory and production workshop. Committed to providing high-purity raw materials and excellent customer service, we sincerely hope to cooperate with you.